Comparison of dose-dense vs. 3-weekly paclitaxel and carboplatin in the first-line treatment of ovarian cancer in a propensity score-matched cohort

BACKGROUND: Benefit of carboplatin and dose-dense weekly paclitaxel (ddCT) in first line treatment of ovarian cancer patients has been different in Western and Asian studies. In the present study we compare progression-free survival (PFS) of ddCT to three-weekly carboplatin and paclitaxel (CT) in fi...

Descripción completa

Detalles Bibliográficos
Autores principales: Pirolli, Rafaela, de Alencar, Viviane Teixeira Loiola, Estati, Felipe Leonardo, Ribeiro, Adriana Regina Gonçalves, Honda, Daniella Yumi Tsuji, de Oliveira, Mariana, da Silveira Nogueira Lima, Joao Paulo, dos Santos, Elizabeth Santana, Guimarães, Andrea Paiva Gadelha, Baiocchi, Glauco, da Costa, Alexandre André Balieiro Anastácio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8106841/
https://www.ncbi.nlm.nih.gov/pubmed/33964923
http://dx.doi.org/10.1186/s12885-021-08270-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8106841/
https://www.ncbi.nlm.nih.gov/pubmed/33964923
http://dx.doi.org/10.1186/s12885-021-08270-0

Ejemplares similares